The efficacy and safety of medical therapies assessed on the basis of short-term outcomes are often considered to inform the long-term outcomes. Even in corticosteroid therapy, either systemic or topical, which is most frequently used as a first-line therapy to control inflammation, few studies have reported the risk/benefit ratio for long-term outcomes. Thus, a temporal perspective should be added to our conventional understanding of the effectiveness of medical therapies. In this review, we initially describe the importance of considering the efficacy of corticosteroid therapy based not only on short-term outcomes, but also on long-term outcomes of a certain type of severe drug eruption, drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DiHS/DRESS). Our view is exemplified by our recent analysis of previously reported cases of DiHS/DRESS, revealing that aggressive treatment such as pulsed corticosteroids and intravenous immunoglobulin, although beneficial in the short term, paradoxically has deleterious effects such as autoimmune sequelae in the long term. Thus, measuring the therapeutic efficacy from only a short-term perspective is insufficient and follow-up examination of these patients for at least three years is required even after complete resolution is observed. Various cutaneous diseases refractory to conventional therapies that occur after resolution of herpes zoster also require a temporal perspective to understand how cutaneous diseases develop at a certain site. We describe the clinical usefulness of considering the dual actions of corticosteroids, antiinflammatory, and immunostimulatory, depending on the situations in which they are used.
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| INTRODUCTION
Corticosteroids, either topical or systemic, are most frequently used as a first-line therapy to control inflammation in patients with autoimmune diseases and cutaneous inflammatory diseases. The safety of corticosteroid use over long periods, however, is always a concern, although previous long-term, controlled studies suggest that long-term adverse effects, such as osteonecrosis, are uncommon when the corticosteroid dosage is low. 1, 2 Thus, it is important to investigate whether the efficacy and safety in the short term necessarily assure the safety and efficacy in the long term. Even in corticosteroid therapy, however, few studies have demonstrated the risk/ benefit ratio in the long term; an excellent risk-benefit ratio of a certain therapy in the short term may not be necessarily favorable in the long term. It is also difficult to evaluate the effectiveness of medical therapy because of the effect of the disease duration before therapy is started; if treated early, many patients might have a life expectancy similar to that in a healthy control population, but if treatment is delayed, patients with late-stage disease might have a significantly greater risk of morbidity and mortality. Thus, a temporal perspective should be added to our conventional understanding of the effectiveness of medical therapy.
In addition, considering skin diseases as dynamic processes in which phenotypic manifestations evolve in a continuous manner rather than as a distinct disease onset is important in terms of understanding the pathogenesis or management. Indeed, careful fol- 
| AUTOIMMUNE SEQUELAE IN SEVERE DRUG ERUPTION S
Severe drug eruptions encompass two distinct clinical entities, the most common being drug-induced hypersensitivity syndrome (DiHS)/ drug reaction with eosinophilia and systemic symptoms (DRESS).
Another is Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). On the basis of clinical comparisons as well as immunologic studies of the two diseases, these two forms of severe drug eruptions likely have distinct pathogenic mechanisms, 4,5 although some of the causative drugs are common. DiHS/DRESS is characterized by sequential reactivations of herpesviruses, probably due to functional defects in regulatory T cells (Tregs). 6 Several autoimmune diseases and the generation of autoAbs concurrently or sequentially occur as sequelae of DiHS/DRESS. [7] [8] [9] Inflammation and subsequent damage to the skin and liver in patients with DiHS/DRESS are thought to lead to autoAbs generation and the onset of autoimmune disease. 9 Treatment is therefore aimed at suppressing the inflammation early and preventing the development of tissue destruction. In contrast to the short-term outcome, in which noncorticosteroid treatment was thought to be more beneficial than corticos- 15 days after the detection of CMV reactivation, and the occurrence of these severe complications was mostly prevented in patients in whom anti-CMV therapy was initiated within three days after detecting CMV reactivation. 19 These results suggest that most, if not all, of the complications traditionally considered related or unrelated to CMV reactivations are due to CMV reactivation or related events and would therefore be preventable with anti-CMV therapy.
Because these complications would be treated by nondermatologists who did not care for the patients at the acute stage, the relationship between DiHS/DRESS, and the later development of such fatal complications has received little attention unless suspected from the patients' history. Our results also showed that age over 70 years is associated with the highest risk of later development of CMV reactivation, especially CMV-related fatal complications. 19 Because these complications and autoimmune sequelae occurred around two months (complications) and two to three years (autoimmune sequelae) after onset, respectively, the risk of such late-onset complications and autoimmune sequelae should be carefully considered even in lowrisk patients under 60 years of age. Thus, simply measuring the therapeutic efficacy in the short term could be insufficient and follow-up examinations in DiHS/DRESS patients would be required for at least three years, even after complete resolution is observed. DiHS/DRESS is a serious disease with increased risk of viral reactivation, complications, autoimmune sequelae, and mortality. The resolution of DiHS/ DRESS at the acute stage should no longer be loosely referred to as cured, because our data strongly support the need for improved longterm management for these patients, especially for these serious complications that occur after one to two year disease-free intervals.
| DERMATOSES OCCURRING AFTER OR DURING AN EPISODE OF HE RPES ZOSTER
The usual clinical features of herpes zoster (HZ) are readily recognized. In most cases, the characteristic features of HZ rash establish the clinical diagnosis. Varicella zoster virus (VZV), however, also has an atypical presentation. These lesions encompass folliculitis, 20 syringitis, verruciform lesions, 21 nodular lesions, 22 intracranial hemorrhage, 23 and acute abdomen. 24 Involvement of the hair follicles or eccrine epithelium by VZV is an infrequently described histologic pattern mostly reported in HIV-infected patients and rarely reported even in immunocompetent patients. In these lesions, VZV DNA and VZV-specific antigens such as VZV major envelope glycoprotein (gE) are detected in follicular keratinocytes, the epithelium of eccrine glands, or the gastric epithelium, which may be associated with cytopathic changes with intranuclear inclusions. The diagnosis of HZ can be also confirmed by polymerase chain reaction (PCR) analysis for VZV in the cerebrospinal fluid. Pruritus is also reported in many patients with HZ, not only during the herpetic period, but also in the pre-or postherpetic period. VZV gE can be detected as early as two to three days after the onset of HZ, and expression persists for at least several months in HZ lesions, whereas VZV DNA disappears much earlier than VZV gE antigens. 3 Because VZV gE is an essential late protein expressed on the cell membrane during lytic infection and is a predominant component of the virion envelope, 24, 25 immunohistochemical detection of VZV gE in these lesions, either cutaneous or gastrointestinal, suggests VZV involvement in the development of these lesions.
Severe abdominal pain may occur as a serious manifestation of HZ, known as abdominal zoster, 26, 27 particularly in an immunosuppressed host. 27 In these patients, the diagnosis of abdominal zoster is not usually considered until the typical vesicular eruptions begin to appear. Because the typical vesicular eruptions could be entirely absent in some patients with abdominal zoster, 28 however, the diagnosis in the setting of the absence of cutaneous lesions (zoster sine herpete) can only be made by PCR analysis of blood or saliva and biopsy or autopsy samples. Indeed, autopsy studies reveal high frequencies of abdominal involvement of VZV. 27 In these cases, herpetic lesions on the serosal and mucosal gut wall were observed at laparotomy. In this regard, our previous immunohistochemical study clearly demonstrated that detection of VZV antigens in the eccrine epithelium can be used as a highly reliable and useful clue to the diagnosis of HZ with unusual manifestations and inflammatory dermatoses induced by VZV infection. gastric or enteric zoster. 30 We therefore investigated whether VZV gE antigens could be detected in both cutaneous and gastrointestinal lesions, and whether a significant increase in VZV IgG titers could be specifically detected in IAV patients with severe abdominal pain. 31, 32 We analyzed consecutive IAV patients with severe abdominal mani- The term "postherpetic isotopic response" or "Wolf's isotopic response" encompasses a wide spectrum of clinical entities, ranging from LP to sarcoid granuloma. [33] [34] [35] Among them, granulomatous reactions ranging from granuloma annulare to granulomatous vasculitis at sites of resolved HZ lesions are well described. 34, 36 These granulomatous reactions can occur immediately after the resolution of vesicular lesions, or at various times after the HZ. Earlier studies using PCR, however, failed to identify VZV DNA in the granulomatous reactions arising between one month and up to four years after the resolution of HZ. 37 These results may indicate that persistent expression of VZV gE antigens in the resolved HZ lesions could induce VZV-directed immune responses.
In addition to granulomatous reactions, many cutaneous disorders occur within healed HZ lesions, including LP, lichen simplex chronicus, 38 pseudolymphoma, 39 psoriasis, 40 lichenoid chronic graftvs-host disease, 41 and lymphoma. 42 The term "postherpetic isotopic response" or "Wolf's isotopic response" describes the occurrence of a new, unrelated disease appearing at the same location as previously healed HZ or, rarely, herpes simplex lesions. At present, however, there are no satisfying explanations for how these cutaneous disorders develop at the healed herpetic lesions. Recent reports on herpetic syringitis suggest the involvement of sweat glands in VZV infection. 43 Although localized unilateral hypohidrosis with a dermatomal or segmental distribution is suggestive of VZV involvement, a relationship between localized hypohidrosis and VZV infection has not yet been demonstrated, probably due to the low frequency of detection of VZVDNA in the lesions. Nevertheless, in view of our recent observation that long-lasting hypohidrosis localizing to the involved dermatome in healed HZ lesions is relatively common, 44 hypohidrosis after HZ might contribute to the onset of these secondary isotopic diseases at the involved dermatomes. We recently experienced two patients who developed LP and LA, respectively, in healed HZ lesions, prompting us to question whether hypohidrosis after VZV reactivation could be involved in the development of these isotopic responses. Because these lesions were characterized by dry skin and thought to be induced by postherpetic hypohidrosis, we examined sweating responses to thermal stimulation in these lesions using the impression mold technique, which allows for accurate quantification of the activity of each sweat gland/duct to produce and deliver sweat. 45 humans. These previous analyses were largely performed in mouse models, and thus more patient-based studies are required to address these important issues given the differences in skin physiology between human and mice.
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